Atlas Trials

Vebreltinib for Neoadjuvant in MET-altered Stage IIIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)

Clinical trial NCT06644313 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06644313
Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Potentially Resectable MET-altered Non-Small Cell Lung Cancer
Start date
2024-11-01
Primary completion
2029-11-01
Enrollment
31

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.